Bill Maughan
Stock Analyst at Canaccord Genuity
(0.01)
# 4,406
Out of 4,829 analysts
14
Total ratings
16.67%
Success rate
-37.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bill Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $26 | $3.89 | +568.38% | 2 | Aug 13, 2024 | |
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $1.93 | +677.20% | 2 | May 10, 2024 | |
| FATE Fate Therapeutics | Maintains: Buy | $11 → $9 | $1.04 | +765.38% | 1 | May 10, 2024 | |
| IMCR Immunocore Holdings | Maintains: Hold | $63 → $67 | $28.40 | +135.92% | 3 | May 9, 2024 | |
| MRNA Moderna | Maintains: Hold | $91 → $106 | $24.25 | +337.11% | 3 | May 3, 2024 | |
| IPSC Century Therapeutics | Maintains: Buy | $22 → $24 | $0.54 | +4,369.27% | 1 | Mar 15, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $60 | $8.34 | +619.42% | 1 | Feb 21, 2024 | |
| MRUS Merus | Initiates: Buy | $45 | $40.90 | +10.02% | 1 | Nov 2, 2023 |
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Buy
Price Target: $26
Current: $3.89
Upside: +568.38%
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $1.93
Upside: +677.20%
Fate Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $1.04
Upside: +765.38%
Immunocore Holdings
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $28.40
Upside: +135.92%
Moderna
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $24.25
Upside: +337.11%
Century Therapeutics
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $0.54
Upside: +4,369.27%
Bicycle Therapeutics
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $8.34
Upside: +619.42%
Merus
Nov 2, 2023
Initiates: Buy
Price Target: $45
Current: $40.90
Upside: +10.02%